Research priorities to address supportive care needs in acute myeloid leukaemia (AML)-results from a Delphi survey

A cute myeloid leukaemia (AML) carries major clinical, economic, and psychosocial burdens. Supportive care is critical to prevent mortality and morbidity and support long-term well-being. Many AML trials focus on treating AML disease, but few prospectively evaluate supportive care measures. This study sought to identify AML supportive care research priorities to inform the design of future AML clinical trials.

A three-stage online Delphi process was used. Participants (clinicians and people with lived experience) were invited from Australia and New Zealand through the Australasian Leukaemia and Lymphoma Group (ALLG), the Leukaemia Foundation, and professional networks. Round 1 generated supportive care research question, and in round 2, participants rated each question's importance. A priori criteria were applied for a question to continue to round three. Finally, participants ranked their top 10 research questions and the type of research needed to address each question.

A total of 31 participants completed round one, and 22 in rounds two and three. People with lived experience made up 32% of the sample in round one, 45% in round two, and 27% in round three. Round one resulted in 66 research questions across 13 domains. In round two, from the initial 66 questions, 16 (24%) met the criteria to progress to the next round. In the final round, participants agreed on 10 priority research questions.

This Delphi process identified ten supportive care research priorities in AML across many domains, including infection management, bleeding prevention, nutrition, exercise, and frailty assessments. This work, which incorporates people with lived experience, can be used to inform design of future AML trials.